Abstract
* The daily dosage of the anti-depressant citalopram (Celexa) has now been limited to 40 mg because of potential dose-dependent QT prolongation and the risk of life-threatening arrhythmias.
* The label for the atypical antipsychotic asenapine (Saphris) has been revised to warn of possibly serious allergic reactions, including anaphylaxis and angioedema.